Mountain Valley MD Provides Business Update, Appoints New CFO

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a broad business update of its progress across its three core lines of business:

1. Nutraceuticals - novel innovations through the Company’s Quicksome technology that are designed to improve the administration and efficacy of nutraceutical health and wellness products;
2. Agriculture – the Company’s licensed Agrarius agricultural plant signaling technology that is designed to organically drive increases in crop yields and overall plant health; and
3. Husbandry Animals/Aquatic Species - the application of solubilized drugs through the Company’s Quicksol technology that is designed to positively impact the health of husbandry animals and aquatic species.

“We believe are at a very exciting time in our Company’s progress. The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD. “We are confident that the tangible value proposition of our technologies is being very well received and that we have successfully laid the groundwork needed to support our long-term commercial viability, while supporting our desire to make a global impact in line with our vision of More Life.”

BUSINESS UPDATES

NUTRACEUTICALS

Quicksome Powered Eons Deeper Sleep Product Launched

MVMD’s contracted manufacturing partner in the U.S. (“Lead Manufacturer”) has completed the set-up and testing of equipment to enable the proprietary production of nutraceutical applications for MVMD’s Quicksome technology, including sublingual rapid dissolve tablets and powders. The GMP manufacturing and initial consumer order fulfilment for the first product to embody the Quicksome technology was completed in February 2024 with the Eons Deeper Sleep rapid dissolve mushroom tablet product. The Eons product was produced by Circadian Wellness Corp. (“CW”) under license from MVDM and is available to purchase directly from the CW’s website at eons.com.

The Company has demonstrated through third-party and in-house studies that its patented liposomal Quicksome technology uses proprietary formulations and stabilizing agents to encapsulate active ingredients, enabling a more optimized delivery into the body through sublingual applications when compared to orally consumed pills. When the Quicksome technology is consumed sublingually, the Company believes there is an increase in the overall efficacy of the active ingredients, a reduction in variability of impact, and promotes the ability to use less actives versus competitive products.